Article Text

PDF
Genetic screening for pheochromocytoma: should SDHC gene analysis be included?
  1. M Mannelli1,
  2. T Ercolino1,
  3. V Giachè1,
  4. L Simi2,
  5. C Cirami3,
  6. G Parenti1
  1. 1Endocrinology, Department of Clinical Physiopathology, University of Florence, Florence, Italy
  2. 2Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy
  3. 3U.O. Nephrology, Azienda Ospedaliera Careggi, Florence, Italy
  1. Correspondence to:
 Massimo Mannelli
 MD, Full Professor of Endocrinology, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy; m.mannelli{at}dfc.unifi.it

Abstract

PGL3 syndrome is caused by mutations in the SDHC gene. At present, only a few families affected by SDHC mutations have been reported in the literature and in each of them the clinical presentation was characterised by paragangliomas located only in the head and neck regions. No evidence of thoracic or abdominal catecholamine-secreting chromaffin tumours has been reported to date. We report the case of a 15-year-old girl with hypertension and a norepinephrine-secreting abdominal paraganglioma who was found to harbour a novel nonsense SDHC mutation, demonstrating that the clinical presentation of PGL3 syndrome can be more diverse than expected.

  • SDH, succinate dehydrogenase
  • PGL3
  • W42X
  • paraganglioma
  • neural crest derived tumors
  • genetic testing

Statistics from Altmetric.com

Footnotes

  • Competing interests: None declared.

  • Published Online First 8 June 2007

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.